BUSINESS BRIEF
The company manufactures pharmaceuticals and specialty chemicals, focusing on intermediates, APIs, and cosmetic compounds. It has established strong B2B client relationships. It is presently operating below full capacity, offering significant potential for growth. A targeted product portfolio drives steady revenue, and with the existing management team, the business can scale efficiently in the near future.
Investment Highlights:
- High Growth: Significant potential to scale revenues with expansion
- Experienced Leadership: Management with deep pharma and quality expertise
- Oncology APIs: New segment with high potential and margins
NOTE: Need capital to grow the business. Also open to getting a strategic investor/JV partner and continue the business as next generation is also well qualified and fully involved.
Products & Services
- APIs
- Cosmetic Ingredients
- Pharmaceutical Intermediates
Additional Information
Valuation - To be Discussed
Proposal
Industry
Pharmaceuticals
Sub Industry
Pharmaceutical Manufacturing (Bulk Drug & API) & Integrated Pharma
Nature of Business
B2B
Sector
Manufacturing (Own Brand & Contract Manufacturing)
Reason for sell-off
Capitalizing on Market Position or Valuation
Location
India
Region
Southern
Open For Dilution
100 % (Complete Buyout)
Top Customer
Deal Size
INR 45 - 50 Cr
Justification
Based on market multiple
Business Operation Information
Financial Information |
2025 (in INR Cr) | 2024 (in INR Cr) | 2023 (in INR Cr) |
|---|---|---|---|
Sales |
37.56 | 19.44 | 7.10 |
EBITDA |
|||
PAT |
N.D |
